Antiphospholipid antibody associated thrombosis: A consensus for treatment?

Lupus

Volumn 5, Issue 6, 1996, Pages 560-570

  McCrae, K R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Lupus anticoagulant; Thrombosis; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; HUMAN; PRIORITY JOURNAL; RISK; VEIN THROMBOSIS;

EID: 0030445489     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500602     Document Type: Article

References (39)

1. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430.
2. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In Spaet TH (ed). Progress in Hemostasis and Thrombosis. Grune Stratton: New York, 1972; 75-87.
3. Boey ML et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Lancet 1983; 287: 1021-1023.
4. Elias M, Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant. Arch Int Med 1984; 144: 510-515.
5. Mueh JR, Herbst KD, Rapaport SI Thrombosis in patients with the lupus anticoagulant. Ann Int Med 1980; 92: 156-159.
6. Hughes GRV. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 289: 1088-1089.
7. Harris EN et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-1214.
8. Harris EN et al. Thrombosis, recurrent fetal loss and thrombocytopenia: Predictive value of the anticardiolipin antibody test. Arch Int Med 1986; 146: 2153-2156
9. Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): First report from the Italian registry. Haematologica 1993; 78: 313-318.
10. Ginsburg KS et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis Ann Int Med 1992; 117: 997-1002.
11. Hamsten A et al. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986; ii: 113-115
12. Morton KE et al. Coronary artery bypass graft failure - an autoimmune phenomenon?. Lancet 1986; ii: 1353-1356.
13. Levine SR, Brey RL, Joseph CLM, Havstad S. Antiphospholipid Antibodies in Stroke Study Group: Risk of recurrent thromembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies Stroke 1992; 23 (suppl. 1): 129-132.
14. Asherson RA et al. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis 1985; 44: 823-825.
15. Asherson RA, Baguley E, Pal C, Hughes GRV. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis 1991; 50: 805-810.
16. Derksen RHWM, De Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-692.
17. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-308.
18. Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
19. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Int Med 1992; 232: 155-160.
20. Hull R et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
21. Hull R et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
22. Schulman S et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
23. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-159.
24. Hull R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-1681.
25. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
26. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant patients. Arch Int Med 1993; 153: 1557-1562.
27. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120: 897-902.
28. Fihn SD et al. Risk factors for complications of chronic anticoagulation. Ann Int Med 1993; 118: 511-520.
29. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment Chest 1992; 102 (suppl.): 352S-363S.
30. Ginsberg JS et al. Antiphosphilipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
31. Krnic S et al. Clinical, laboratory and treatment factors influencing recurrent thrombosis in the antiphospholipid syndrome. (submitted for publication).
32. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheum 1992; 19: 508-512.
33. Ferro D, Quintarelli C, Valesini G, Violi F. Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. Blood 1994; 83: 304.
34. Ginsberg JS et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state. Blood 1993; 81: 2958-2963.
35. Galli M et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1554-1559.
36. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4125.
37. Matsuura E et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 335: 177-178.
38. Shi W et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990; 20: 231-236.
39. Barbui T, Finazzi G. Clinical trials on antiphospholipid syndrome: What is being done and what is needed?. Lupus 1994; 3: 303-307.